Celldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed as Buy by HC Wainwright

Posted by on Oct 2nd, 2026

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $64.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 102.21% from the stock’s current price.

Other research analysts have also issued reports about the stock. Guggenheim raised their price target on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. Stifel Nicolaus set a $68.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, September 22nd. Barclays raised their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.92.

Get Our Latest Research Report on Celldex Therapeutics

Celldex Therapeutics Stock Down 1.6%

Shares of CLDX stock traded down $0.53 during mid-day trading on Friday, hitting $31.65. 2,404,662 shares of the stock were exchanged, compared to its average volume of 1,064,734. The firm has a fifty day moving average of $38.45 and a 200 day moving average of $34.91. Celldex Therapeutics has a 52-week low of $22.10 and a 52-week high of $45.14. The company has a market cap of $2.49 billion, a PE ratio of -7.28 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.74 million. Equities analysts predict that Celldex Therapeutics will post -4.17 EPS for the current year.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently bought and sold shares of CLDX. Handelsbanken Fonder AB lifted its position in Celldex Therapeutics by 5.0% in the second quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 1,300 shares during the last quarter. Nykredit A S purchased a new position in Celldex Therapeutics during the second quarter worth about $67,000. Arizona State Retirement System increased its position in shares of Celldex Therapeutics by 13.0% during the second quarter. Arizona State Retirement System now owns 18,565 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 2,139 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Celldex Therapeutics by 8.4% during the fourth quarter. Intech Investment Management LLC now owns 33,499 shares of the biopharmaceutical company’s stock valued at $910,000 after acquiring an additional 2,608 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Celldex Therapeutics by 3.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 77,772 shares of the biopharmaceutical company’s stock valued at $2,467,000 after acquiring an additional 2,642 shares during the period.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.

Read More

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.